对“使用双硫仑/依布硒啉和瑞德西韦协同抑制新型冠状病毒复制”的更正。
Correction to "Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir".
作者信息
Chen Ting, Fei Cheng-Yin, Chen Yi-Ping, Sargsyan Karen, Liang Jian-Jong, Liao Chun-Che, Lin Yi-Ling, Chang Chun-Ping, Yuan Hanna S, Lim Carmay
机构信息
Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.
Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan.
出版信息
ACS Pharmacol Transl Sci. 2021 Apr 29;4(3):1246. doi: 10.1021/acsptsci.1c00106. eCollection 2021 Jun 11.
Abstract
[This corrects the article DOI: 10.1021/acsptsci.1c00022.].
摘要
[本文更正了文章DOI：10.1021/acsptsci.1c00022。]
相似文献
1
Correction to "Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir".对“使用双硫仑/依布硒啉和瑞德西韦协同抑制新型冠状病毒复制”的更正。
ACS Pharmacol Transl Sci. 2021 Apr 29;4(3):1246. doi: 10.1021/acsptsci.1c00106. eCollection 2021 Jun 11.
2
Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir.使用双硫仑/依布硒啉和瑞德西韦协同抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）复制
ACS Pharmacol Transl Sci. 2021 Mar 26;4(2):898-907. doi: 10.1021/acsptsci.1c00022. eCollection 2021 Apr 9.
3
Correction to "Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity".对《靶向组织蛋白酶的新型 SARS-CoV-2 抑制剂：设计、合成及生物活性》的修正
ACS Pharmacol Transl Sci. 2024 Mar 6;7(4):1195-1196. doi: 10.1021/acsptsci.4c00095. eCollection 2024 Apr 12.
4
Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors.依布硒啉、双硫仑、卡莫氟、PX-12、替德吉布和紫草素是非特异性混杂的新型冠状病毒2型主要蛋白酶抑制剂。
ACS Pharmacol Transl Sci. 2020 Oct 9;3(6):1265-1277. doi: 10.1021/acsptsci.0c00130. eCollection 2020 Dec 11.
5
Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives.埃布斯硒啉及其衍生物对 SARS-CoV-2 主蛋白酶的抑制机制。
Nat Commun. 2021 May 24;12(1):3061. doi: 10.1038/s41467-021-23313-7.
6
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.预防性和治疗性瑞德西韦（GS-5734）治疗中东呼吸综合征冠状病毒感染恒河猴模型。
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776. doi: 10.1073/pnas.1922083117. Epub 2020 Feb 13.
7
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir.瑞德西韦抑制 SARS-CoV-2 的 RNA 依赖性 RNA 聚合酶的结构基础。
Science. 2020 Jun 26;368(6498):1499-1504. doi: 10.1126/science.abc1560. Epub 2020 May 1.
8
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.瑞德西韦是一种直接作用的抗病毒药物，能高效抑制严重急性呼吸综合征冠状病毒 2 的 RNA 依赖性 RNA 聚合酶。
J Biol Chem. 2020 May 15;295(20):6785-6797. doi: 10.1074/jbc.RA120.013679. Epub 2020 Apr 13.
9
Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.揭示瑞德西韦和核苷酸类似物对 SARS-CoV-2 的 RNA 依赖性 RNA 聚合酶（RdRp）的抑制机制：分子动力学模拟研究。
J Phys Chem B. 2020 Nov 25;124(47):10641-10652. doi: 10.1021/acs.jpcb.0c06747. Epub 2020 Nov 15.
10
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.瑞德西韦在人肺细胞和表达 SARS-CoV-2 聚合酶的嵌合 SARS-CoV 小鼠中抑制 SARS-CoV-2。
Cell Rep. 2020 Jul 21;32(3):107940. doi: 10.1016/j.celrep.2020.107940. Epub 2020 Jul 7.
引用本文的文献
1
A Multiallelic Molecular Beacon-Based Real-Time RT-PCR Assay for the Detection of SARS-CoV-2.一种基于多等位基因分子信标的实时逆转录聚合酶链反应检测法用于检测严重急性呼吸综合征冠状病毒2
Life (Basel). 2021 Oct 27;11(11):1146. doi: 10.3390/life11111146.
Zotero 插件